| pubmed-article:238815 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:238815 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
| pubmed-article:238815 | lifeskim:mentions | umls-concept:C0034721 | lld:lifeskim |
| pubmed-article:238815 | lifeskim:mentions | umls-concept:C0034693 | lld:lifeskim |
| pubmed-article:238815 | lifeskim:mentions | umls-concept:C0025519 | lld:lifeskim |
| pubmed-article:238815 | lifeskim:mentions | umls-concept:C0014806 | lld:lifeskim |
| pubmed-article:238815 | lifeskim:mentions | umls-concept:C0058632 | lld:lifeskim |
| pubmed-article:238815 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:238815 | pubmed:dateCreated | 1975-11-6 | lld:pubmed |
| pubmed-article:238815 | pubmed:abstractText | The absorption, excretion, and metabolism of [1-14C]lauryl sulfate as either the sodium or propionyl erythromycin salt has been studied in the rat and man. In the rat 88% of the radiolabel from propionyl erythromycin [1-14C]lauryl sulfate was excreted in the urine in the 24-hr period following a single oral dose. More than 95% of the radiolabel was excreted as the metabolite butyric acid 4-sulfate. This metabolite was shown to be derived from carbons 1-4 of the lauryl sulfate moiety. There was no evidence of sulfate cleavage in the rat. In man 51-59% of the administered ratioactivity was recovered in the urine. The major excretion product was butyric acid 4-sulfate accounting for approximately 95% of urinary radioactivity. The remainder was unchanged lauryl sulfate. A significant portion of the radiolabeled propionyl erythromycin lauryl sulfate was converted to 14CO2 indicating that the sulfate linkage was cleaved. A minimum value of 9-16% of the dose was metabolized in this manner. | lld:pubmed |
| pubmed-article:238815 | pubmed:language | eng | lld:pubmed |
| pubmed-article:238815 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:238815 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:238815 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:238815 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:238815 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:238815 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:238815 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:238815 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:238815 | pubmed:issn | 0090-9556 | lld:pubmed |
| pubmed-article:238815 | pubmed:author | pubmed-author:McMahonR ERE | lld:pubmed |
| pubmed-article:238815 | pubmed:author | pubmed-author:CrabtreeR ERE | lld:pubmed |
| pubmed-article:238815 | pubmed:author | pubmed-author:RidolfoA SAS | lld:pubmed |
| pubmed-article:238815 | pubmed:author | pubmed-author:MurphyP JPJ | lld:pubmed |
| pubmed-article:238815 | pubmed:author | pubmed-author:WilliamsT LTL | lld:pubmed |
| pubmed-article:238815 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:238815 | pubmed:volume | 3 | lld:pubmed |
| pubmed-article:238815 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:238815 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:238815 | pubmed:pagination | 164-70 | lld:pubmed |
| pubmed-article:238815 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:238815 | pubmed:meshHeading | pubmed-meshheading:238815-H... | lld:pubmed |
| pubmed-article:238815 | pubmed:meshHeading | pubmed-meshheading:238815-A... | lld:pubmed |
| pubmed-article:238815 | pubmed:meshHeading | pubmed-meshheading:238815-F... | lld:pubmed |
| pubmed-article:238815 | pubmed:meshHeading | pubmed-meshheading:238815-R... | lld:pubmed |
| pubmed-article:238815 | pubmed:meshHeading | pubmed-meshheading:238815-C... | lld:pubmed |
| pubmed-article:238815 | pubmed:meshHeading | pubmed-meshheading:238815-D... | lld:pubmed |
| pubmed-article:238815 | pubmed:meshHeading | pubmed-meshheading:238815-L... | lld:pubmed |
| pubmed-article:238815 | pubmed:meshHeading | pubmed-meshheading:238815-M... | lld:pubmed |
| pubmed-article:238815 | pubmed:meshHeading | pubmed-meshheading:238815-E... | lld:pubmed |
| pubmed-article:238815 | pubmed:meshHeading | pubmed-meshheading:238815-C... | lld:pubmed |
| pubmed-article:238815 | pubmed:meshHeading | pubmed-meshheading:238815-T... | lld:pubmed |
| pubmed-article:238815 | pubmed:meshHeading | pubmed-meshheading:238815-I... | lld:pubmed |
| pubmed-article:238815 | pubmed:meshHeading | pubmed-meshheading:238815-E... | lld:pubmed |
| pubmed-article:238815 | pubmed:articleTitle | Metabolism of propionyl erythromycin lauryl sulfate. II. Fate of the lauryl sulfate moiety in the rat and man. | lld:pubmed |
| pubmed-article:238815 | pubmed:publicationType | Journal Article | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:238815 | lld:pubmed |
